Intensity Therapeutics Inc (INTS) concluded trading on Thursday at a closing price of $0.39, with 4.04 million shares of worth about $1.58 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -84.92% during that period and on May 29, 2025 the price saw a gain of about 24.00%. Currently the company’s common shares owned by public are about 15.26M shares, out of which, 10.02M shares are available for trading.
Stock saw a price change of 3.73% in past 5 days and over the past one month there was a price change of -35.21%. Year-to-date (YTD), INTS shares are showing a performance of -77.90% which decreased to -92.30% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.29 but also hit the highest price of $5.10 during that period. The average intraday trading volume for Intensity Therapeutics Inc shares is 279.32K. The stock is currently trading -16.10% below its 20-day simple moving average (SMA20), while that difference is down -67.90% for SMA50 and it goes to -84.65% lower than SMA200.
Intensity Therapeutics Inc (NASDAQ: INTS) currently have 15.26M outstanding shares and institutions hold larger chunk of about 14.16% of that.
The stock has a current market capitalization of $7.16M and its 3Y-monthly beta is at 4.02. It has posted earnings per share of -$1.06 in the same period. It has Quick Ratio of 0.63 while making debt-to-equity ratio of 0.39. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INTS, volatility over the week remained 14.41% while standing at 7.82% over the month.
Analysts are in expectations that Intensity Therapeutics Inc (INTS) stock would likely to be making an EPS of -0.18 in the current quarter, while forecast for next quarter EPS is -0.16 and it is -0.47 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.18 which is -0.18 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 43.38% while it is estimated to increase by 18.99% in next year. EPS is likely to grow at an annualized rate of 17.65% for next 5-years, compared to annual growth of -23.29% made by the stock over the past 5-years.
